Healthcare
Precigen, Inc.(PGEN)
Live Price
Offline$4.45
-1.77% today
1Y Change
+141.89%
Window
Jun 23, 2025 โ Jun 5, 2026
- Market Cap
- $1.23B
- Revenue Growth
- +146.7%
- EPS Growth
- -200.0%
- Dividend Yield
- 0.0%
Coverage: 240 bars ยท Jun 23, 2025 โ Jun 5, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Precigen, Inc. (PGEN) is a Healthcare stock with a market cap of $1.23B and listed on NASDAQ. The stock last traded around $4.45 and up 141.9% across the available one-year price window (Jun 23, 2025 โ Jun 5, 2026). Baseline metrics include revenue growth of +146.7%, EPS growth of -200.0%, a dividend yield of 0.0%. What stands out right now is revenue +146.7%, EPS -200.0%, free cash flow -17.0% with operating margin -1141.1% and ROIC -91.7%. Valuation already assumes a fairly strong business story at price/sales 126.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PGEN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+146.7% vs +7.6% peer median
Operating Margin
Below sector median
-1141.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +146.7% and EPS is at -200.0%, with operating margin around -1141.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +10.2% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | +10.8% | +2.9% | โ |
2026 Mar 25, 2026 | +90.0% | +25.5% | +26.8% | +27.7% |
2025 Nov 13, 2025 | -37.5% | +25.6% | +1.0% | -4.4% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PGEN
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PGEN Max Drawdown
-40.50%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PGEN and SPY.
Company Overview
Precigen, Inc.
NASDAQ Global Select
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
- Leadership
- Helen Sabzevari
- IPO Date
- Aug 8, 2013
- Employees
- 143
- Street Address
- 20374 Seneca Meadows Parkway
- Mailing
- Germantown, MD, 20876
- Region
- Germantown, MD, US
- Reporting Currency
- USD
- Investor Line
- 301 556 9900
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 126.6
- Price/Book
- 61.1
Growth
- Revenue
- +146.7%
- EPS
- -200.0%
- Free Cash Flow
- -17.0%
Profitability
- Gross Margin
- 42.1%
- Operating Margin
- -1141.1%
- Net Margin
- -2588.2%
- ROE
- -8396.7%
- ROIC
- -91.7%
Balance Sheet
- Debt/Equity
- 0.24
- Current Ratio
- 3.09
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.